Back to all announcements

DJ Rutherford Health PLC Agreement with NHS SBS

TIDMRUTH

RNS Number : 5218N

Rutherford Health PLC

21 May 2020

20 May 2020

RUTHERFORD HEALTH PLC

AGREEMENT WITH NHS SBS

Rutherford Health plc (the "Company" or "Group" or "Rutherford") is delighted to announce that it has entered into a framework agreement with NHS Shared Business Services ("NHS SBS"), under which it is able to provide cancer treatment services on demand by any NHS Trust at a pre-agreed set of prices. The agreement lasts for two years with an option to extend for a further two years on the agreement of both parties. The agreement covers the complete range of services that Rutherford offers, including radiotherapy, systemic anti-cancer therapy (chemotherapy), proton beam therapy and diagnostic services.

NHS SBS was established by the Department of Health and Social Care (DHSC) in a unique partnership with digital experts Sopra Steria. NHS SBS delivers modern corporate services to the NHS, which improve efficiency and quality, save time and money, and support world-class patient care. Further information about NHS SBS can be found at https://www.sbs.nhs.uk/ .

Mike Moran, Rutherford's CEO commented: "We are absolutely delighted to have signed this agreement with NHS SBS. We have been supplying radiotherapy and systemic anti-cancer therapy to NHS patients in England and Wales and proton beam therapy to a small number of adult NHS patients in Wales under contracts with individual NHS Trusts. This agreement streamlines the procurement process and enables any NHS Trusts in England and Wales to order services directly from us. It means that we are now in a position to expand the services we actually provide.

"I am particularly delighted to be supporting the fantastic work that the NHS are doing at this incredibly difficult time by providing these critically needed cancer treatments and services in dedicated cancer treatment facilities, relieving the pressure on NHS hospitals".

Phil Davies, Director of Procurement at NHS commented: "NHS organisations routinely acquire extra clinical capacity to deal with spikes in demand and to keep waiting lists down for patients. The recent extreme pressure on NHS services means that additional clinical support is likely to be needed now more than ever. We have worked with a number of NHS trusts to put a framework in place that enables any NHS provider to access high-quality clinical services quickly - in a cost-effective and compliant manner."

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

The directors of Rutherford Health plc accept responsibility for this announcement.

Contacts

 
Rutherford Health plc 
Michael Moran, Chief Executive Officer      Tel: +44 (0) 16 3381 
                                                            0661 
 
Grant Thornton (Corporate Adviser)          Tel: +44 (0) 20 7383 
                                                            5100 
Colin Aaronson / Niall McDonald 
 
Media House International                  07788 414 856 or 0207 
                                                        710 0020 
Ramsay Smith                            ramsay@mediahouse.co.uk# 
 
 

About Rutherford Health plc

Rutherford Health plc is at the vanguard of advancing cancer care. Developing and building a network of oncology centres across the UK known as the Rutherford Cancer Centres, offering a comprehensive range of cancer treatments to patients.

The first centre in Newport, South Wales, was the first in the UK to offer high energy proton therapy. In addition, each centre also offers radiotherapy, chemotherapy, immunotherapy, diagnostic imaging and supportive care services.

As well as the Rutherford Cancer Centre South Wales, Rutherford Health plc (formerly known as Proton Partners International Limited) has opened two further centres - the Rutherford Cancer Centre North East in Northumberland and the Rutherford Cancer Centre Thames Valley in Reading, with proton therapy now available in both. Construction of a fourth site in Liverpool, the Rutherford Cancer Centre North West, is now complete and awaiting fitting out.

Rutherford Health plc has partnered with world-leading healthcare technology providers to equip each centre with the very latest and innovative technology, including IBA, Philips and Elekta.

Rutherford Health plc was founded in 2015 by Mike Moran MBE and UK and international cancer experts, including Professor Edward Karol Sikora, former head of the World Health Organisation's cancer programme.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NEXAMMJTMTATBTM

(END) Dow Jones Newswires

May 21, 2020 02:00 ET (06:00 GMT)